302
Views
5
CrossRef citations to date
0
Altmetric
Connective Tissue Diseases and Related Disorders

Clinicopathological characteristics and renal outcomes of childhood-onset lupus nephritis with acute kidney injury: A multicenter study

, , , , , , , , & show all
Pages 970-976 | Received 27 Feb 2018, Accepted 02 Oct 2018, Published online: 18 Dec 2018
 

Abstract

Objectives: Acute kidney injury (AKI) at onset of adult systemic lupus erythematosus (SLE) is a risk factor for end stage kidney disease (ESKD). However, data on childhood-onset lupus nephritis (LN) with AKI are scarce.

Methods: We retrospectively reviewed the complete files of pediatric SLE patients from 1995 to 2010. All patients underwent kidney biopsy promptly after diagnosis.

Results: Thirty-six patients (10 males and 26 females) were enrolled. Mean age at diagnosis and observation period were 11.6 ± 2.4 and 8.1 ± 4.4 years, respectively. Seven patients had AKI at onset of SLE. Compared with those without AKI, patients with AKI had significantly higher proportions of pathologically proliferative LN. Only one patient with AKI progressed to ESKD without complete recovery of renal function. Overall and renal survival rates were 100and 97.2%, respectively. There was no significant difference in estimated glomerular filtration rate at the final visit (85ml/min/1.73 m2 in the AKI group vs. 103.2 ml/min/1.73 m2 in the non-AKI group; p = .11).

Conclusion: Our study demonstrated favorable renal outcomes in childhood-onset LN with AKI in the near to midterm period. Inducing complete remission may be important for preserving renal function.

Acknowledgements

We thank Richard Robins, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Conflict of interests

Kazumoto Iijima reports grants from Astellas Pharma Inc. lecture and/or consulting fees from Pfizer Japan, Inc., Asahi Kasei Pharma Corp., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited. All other authors have declared no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.